Articles tagged with Cancer Medication
African-American men with advanced prostate cancer respond better to anti-androgen drugs and steroids than white men, according to a Duke University Medical Center study. The study suggests potential strategies for improving survival rates among black patients.
The study of SOCS1 and JAK proteins reveals a detailed structure that may guide the development of new cancer drugs. The protein pair is implicated in driving diseases including cancer and inflammatory conditions.
Researchers at the University of California San Diego School of Medicine have found that treatment with cirmtuzumab measurably inhibited the 'stemness' of CLL cells, allowing most patients to forego additional therapy for over eight months. The drug targets ROR1, a molecule exploited by cancer cells to promote tumor growth and spread.
Researchers developed a precision-medicine approach using patient-derived organoids to predict treatment responses in pancreatic cancer. The method identified specific gene signatures that can guide the selection of chemotherapy regimens, offering hope for improved survival rates and quality of life.
The US Department of Energy's Oak Ridge National Laboratory has developed a new method to produce actinium-227, a key radioisotope for the cancer drug Xofigo. This will ensure a sustainable supply of the drug, which is used to treat prostate cancer that no longer responds to hormonal or surgical treatment.
Researchers found that an antifungal medication can halt the growth of dormant cells within bowel tumours in mice. The study suggests that this drug could be effective in treating advanced bowel cancer by targeting drug-resistant cells.
Cancer cells use lipid molecules as fuel when blood supply is low, helping them evade antiangiogenic treatment. A new mechanism suggests that blocking lipid energy pathways could improve cancer treatment outcomes.
A novel data-driven approach called PanDrugs prioritizes cancer treatments based on patient genetic alterations. The method integrates pathway context and collective gene impact to provide therapeutic options for patients with limited druggable genes.
Researchers found that SHP2 inhibitors are effective against lung and pancreatic cancers, which share the same genetic error. The new class of drugs may help treat drug-resistant tumors by reverting cancer cells to being susceptible to other drugs.
A preclinical study found that combining soy lecithin with an NSAID increased anticancer properties and reduced gastrointestinal bleeding. The combination provided superior protection against colorectal cancer without the usual side effects, according to researchers at UTHealth.
Scientists have developed a new approach to cancer therapy by combining two synergistic drug components into a dimer, which can be loaded into polymeric nanotransporters at exceptionally high concentration. This method reduces side effects and improves transport and accumulation of drugs in tumors.
A Penn-led trial has shown that AZEDRA can significantly reduce cardiovascular side effects and stop tumor growth in patients with pheochromocytoma and paraganglioma. The drug is effective in controlling tumor size while also alleviating debilitating symptoms caused by excess hormone production.
Researchers from the University of Virginia have established new guidelines for scientists mapping out the body molecule by molecule to better understand how cells use metals. The guidelines aim to prevent pitfalls that could compromise work in X-ray crystallography, a technique used to reveal small molecular structures.
St. Jude Children's Research Hospital is launching St. Jude Global, a $100M initiative aiming to increase access to care for children with cancer globally within the next decade. The program focuses on education, capacity building, and research to improve childhood cancer survival rates worldwide.
A 5-year lifestyle counseling program for adult men was linked with a reduced risk of developing cancers related to overweight, diet, and smoking over 25 years. The study found that changes to a healthier diet and stopping smoking in adulthood can reduce the risk of some cancer forms.
A cancer patient with advanced ovarian cancer responded well to treatment with hydroxychloroquine and quinacrine, initially prescribed for an autoimmune disease. The case report suggests that repurposing antimalarial drugs may improve cancer outcomes.
Researchers developed a mouse model of luminal bladder cancer to study its therapeutic efficacy, focusing on checkpoint inhibitors and neo-antigens. The model revealed lower levels of immune cells in luminal tumors and differences in neo-antigen expression between subtypes.
The Los Angeles Cancer Surveillance Program, managed by Keck School of Medicine and USC Norris Comprehensive Cancer Center, has improved the understanding, prevention, and control of cancer for nearly 50 years. The program is one of the largest and most comprehensive cancer registries in the US.
A recent study by Mayo Clinic researchers found that the FDA-approved drug decitabine may be effective in treating triple-negative breast cancer. The study identified a subset of patients who could benefit from this therapy based on the presence of certain critical proteins.
A landmark study has delivered a final verdict on finasteride's impact on prostate cancer, finding it reduces risk without increasing mortality. Finasteride significantly lowers the risk of developing prostate cancer without causing an increased risk of dying from the disease.
USC researchers have identified a remedy to prevent lung metastasis in triple-negative breast cancer, which is the deadliest form of breast cancer. A novel solution uses a nanoparticle to deliver a medication directly to tumors, reducing toxic side effects.
Researchers found that combining erectile dysfunction drugs with the flu vaccine can reduce cancer spread by over 90% in a mouse model. The treatment works by blocking immune cells that suppress the immune system after surgery, allowing natural killer cells to fight cancer more effectively.
A small study of adults with pancreatic cancer reveals that patients with BRCA1 or BRCA2 gene mutations have poorer overall survival rates compared to those without the mutations. However, those with BRCA1 or BRCA2 had better survival rates with platinum-based chemotherapy.
Researchers developed a pill that can detect breast cancer in mice using near-infrared light, reducing the need for mammograms and minimizing radiation exposure. The imaging agent was found to bind specifically to cancer cells with high accuracy, paving the way for potential future applications.
Cleveland Clinic researchers found that lowering cholesterol levels can activate anti-tumor pathways in T-cells, leading to improved cancer-killing success. By reducing intracellular cholesterol, the cells' anti-cancer properties were enhanced.
A meta-analysis of 20 randomised trials found that patients' sex may impact the efficacy of immunotherapy in cancer treatment. Women showed a lower survival benefit compared to men, regardless of cancer type and drug administered.
Scientists have discovered a new compound, metarrestin, that significantly reduces metastasis in human prostate, breast and pancreatic cancer in mice. The compound was found to blow up the complex marker PNC, which indicates cancer cells' ability to spread.
A University of Arizona-led team has discovered the full pathway for activating a protein kinase enzyme, revealing its dynamic movement is crucial for activation. This finding may lead to the development of new anti-cancer drugs that target kinases.
A study by NYU Langone Health and the VA found that increasing numbers of veterans with non-aggressive prostate cancer are opting for watchful waiting or active surveillance. This shift towards more conservative treatment reflects a reversal in decades-long overtreatment, bringing care more in line with best practice guidelines.
Researchers found that patients with mutations in DNA repair genes like ATM and RB1 tend not to live as long as those without. These mutations can make tumor cells more susceptible to certain treatments, bringing potential hope for targeted therapies.
The new model allows researchers to conduct multiple clinical trials across several cancer types, lessen expenses, and increase the likelihood of finding medical solutions. This approach has already led to a new standard of care for chronic myeloid leukemia treatment and expanded program opportunities.
Researchers have identified over 100 potential new targets for cancer treatment using state-of-the-art mass spectrometry technology, which could lead to the development of personalized medicine and targeted therapies.
Children with high-grade brain tumors could benefit from targeted treatment personalized to their genetic mutations. Research found that Avastin, an adult cancer drug, improved survival rates in children with specific MAPK gene mutations.
Researchers at Scripps Research Institute have developed a new method to screen for potential cancer drugs using three-dimensional ball-like aggregates of cells called spheroids. They have identified one compound that affects a key cancer-driving protein, paving the way for more effective treatments.
A new computational strategy simplifies complex cancer biomolecular data by emphasizing patient-to-patient variation in molecular signatures of cancer cells. This approach aims to provide a personalized treatment plan by analyzing the genetic makeup and impaired biological pathways of individual patients.
Cancer cells express specific sugar receptors that can be targeted for better drug delivery. Researchers are developing nanocarrier formulations to accumulate in tumor sites and minimize side effects.
A daily tablet has been shown to significantly reduce the risk of blood clots in cancer patients, with a lower rate of recurrence compared to traditional anticoagulant treatment. The study also found increased bleeding risks with the oral drug rivaroxaban.
Researchers have identified a new vulnerability in drug-resistant melanoma that can be exploited to selectively kill cancer cells. By targeting this vulnerability with vorinostat, resistant tumor cells are killed while sensitive cells remain alive.
A recent study found that the majority of eligible patients receive cancer immunotherapy drugs within four months of FDA approval. However, the researchers noted that these patients are often older than those in clinical trials, which could impact treatment effectiveness.
A randomized clinical trial found that flushing the bladder with a chemotherapy drug immediately after surgery significantly reduces the chances of bladder cancer returning. The study, published in JAMA, showed a 34% reduction in the risk of recurrence for patients receiving the treatment.
A new study by researchers at Albert Einstein College of Medicine and Shanghai Jiao Tong University School of Medicine identified an enzyme that helps cancer cells make the building materials they need to quickly proliferate. Inhibiting this enzyme could slow down cancer growth, leading to more effective treatments.
Researchers at Michigan Medicine's Kellogg Eye Center report cases of uveal effusions and eye inflammation caused by immunotherapy treatments. Ophthalmologists emphasize the importance of referring patients with eye problems to an ophthalmologist, while oncologists should ask about medications that may be causing symptoms.
Researchers created a pioneering 3D cancer model to replicate complex tumor behavior and accelerate treatment development. The model can mimic patients' tumors, allowing doctors to identify the best treatment option based on simple biopsies.
A study published in Health Affairs found that generic options did not significantly reduce prices for the cancer therapy imatinib (Gleevec) after nearly two years of competition. The price drop was only 10 percent, which is significantly lower than expected estimates of 80 percent.
Researchers have discovered that an enzyme called UGT8 drives the progression of basal-like breast cancer, but found that zoledronic acid inhibits UGT8 and prevents its spread. The drug may offer a new hope for treating this aggressive form of breast cancer, which is largely untreatable.
A targeted 'click-to-release' chemotherapy approach has shown promising results in mice, demonstrating effective anticancer effects against ovarian and colon cancers. The innovative method, developed by Tagworks Pharmaceuticals, releases a large quantity of chemotherapy drug quickly, attacking the tumor cells.
A new study has revealed that breast cancer drug lapatinib can cause breast cancer cells to grow more rapidly in some situations. The findings could lead to safer treatment decisions and improved drug design in the future. Researchers hope their results will inform how doctors select patients who may benefit most from these drugs.
Researchers at Duke University have discovered that a cancer drug, Marimastat, can help treat tuberculosis by improving the structural integrity of leaky blood vessels in granulomas. This allows antibiotics to penetrate and attack the disease-causing bacteria more effectively, leading to improved treatment outcomes.
A large-scale study of thyroid cancer genetics has identified specific genes driving the disease and found that certain cancers can benefit from immunotherapy. The research also found amplifications of key receptor tyrosine kinases in anaplastic thyroid cancers, suggesting a potential target for treatment with lenvatinib.
A study found that New York City firefighters exposed to the 9/11 World Trade Center disaster site are at an increased risk for developing myeloma precursor disease, which can lead to the blood cancer multiple myeloma. The prevalence of MGUS was nearly twice as high in firefighters compared to a non-exposed group.
Researchers at the University of California - Berkeley have discovered the molecular structure of human telomerase, a key enzyme in aging and cancer. The detailed picture reveals possible drug-target sites, allowing for more targeted treatments to be developed.
Researchers discovered that baricitinib prevented graft-versus-host disease and even reversed established cases in mouse studies. The drug boosts immune cells to fight cancer while keeping donor T cells from attacking vital organs.
Melissa Chua, a fourth-year medical student at Boston University School of Medicine, has received the Alpha Omega Alpha Carolyn L. Kuckein Student Research Fellowship to conduct research on brain tumors. She is investigating the potential of combining oncolytic virotherapy and immunotherapy for glioblastoma treatment.
Researchers developed a method to 'decorate' gold nanoparticles with proteins, allowing drugs to target specific areas in the body. This technology can improve drug delivery and overcome biological barriers.
Researchers have developed primary pancreatic organoid tumor models using magnetic nanoparticle assembly, enabling high-throughput phenotypic drug screening. These 3D structures allow for the testing of drug-like molecules against patient-derived cancer cells, providing insights into potential patient outcomes.
Using UT Southwestern's largest lung cancer cell library, researchers identified 170 chemicals that could be developed into treatments for non-small cell lung cancer. The team also found biomarkers to predict patient responses and therapeutic targets, paving the way for personalized cancer care.
A new report from the Academy of Medical Sciences warns of the urgent need to address the global burden of multiple serious illnesses. The report suggests that millions worldwide suffer from life-long disability and premature death due to ineffective treatment of people with multiple health conditions.
To address escalating costs of targeted cancer drugs, a Penn-led group proposes three solutions: defining minimum clinically meaningful effect sizes for FDA approval, Medicare negotiating prices for targeted cancer drugs, and prioritizing effective treatments by clinical benefit and price. The recommendations aim to balance clinical be...
Researchers at Cardiff University have developed a new non-toxic method for delivering anti-cancer drugs to specific parts of the body, reducing harsh side effects. The new nanotube delivery method was found to be effective in treating breast cancer, with reduced rates of metastasis and tumour growth.
Researchers have discovered a faster, more cost-effective way to determine which DNA mutations cause human bowel cancer. A new preclinical pipeline uses gene editing technology (CRISPR) to rapidly engineer normal colon cells with DNA changes, allowing for real-time monitoring of growing cancers.